ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0944

L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis

Dayvia Russell1, Soroush Moradi2, Suganya Subramanian2, Silvia Vaena2, Sandra Mungaray2, Stanley Hoffman2, Stefano Berto2 and Jim Oates2, 1Ralph H. Johnson VA, Charleston, SC, 2Medical University of South Carolina, Charleston, SC

Meeting: ACR Convergence 2025

Keywords: Collagen, Gene Expression, Inflammation, Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0934–0954) Systemic Lupus Erythematosus – Animal Models Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a disease of endothelial (EC) dysfunction. We hypothesize that much of this dysfunction stems from uncoupling of endothelial nitric oxide synthase, which leads to inflammatory and fibrotic states in endothelial cells. In the uncoupled state, eNOS produces superoxide rather than nitric oxide. Sepiapterin (PTC923) increases functional coupling of eNOS homodimers through its in vivo product, BH4. We have reported that in a murine model of lupus nephritis (NZM2410), PTC923 improves survival and renal pathology. This study was designed to explore potential mechanisms through which this clinical effect is occurring, with a specific focus on pathways of inflammation, oxidative stress, and fibrosis.

Methods: Female NZM2410 mice were aged to 22 weeks, when NZM2410 mice in our colony develop proteinuria. Mice were randomized to receive either vehicle (n=5) or 20 mg/kg/day (n=5) of PTC923 (L-sepiapterin) for 6 weeks. Mice were euthanized, and renal cortex was harvested for single nuclear RNA sequencing (snRNA-seq). Cell-specific gene markers were used to cluster cells, and differential expression of genes (DEG) was determined for each cell type. DEG with p adjusted < 0.05 and log2fold changed > 1.5 were analyzed. Pathway analysis was performed, and CellChat was used to analyze DEGs and hypothesize potential ligand-receptor interactions between cells.

Results: Endothelial cells (ECs) and proximal tubule (PT) segment 1, 2, and 3 cells were differentially increased PTC923 treatment. Inversely, injured PT cells (iPT), injured ECs (iECs), and T cells were reduced in PTC923 treated mice (Figures 1 and 2). ECs from PTC923-treated mice had increases in genes associated with nitric oxide production. Among iECs, Pdgfc and Pdgfd and among ECs, Pdgfc (associated with signaling for fibrosis) were significantly reduced in PTC923-treated mice. An analysis of redox-regulated genes revealed reductions in pathways that enrich for platelet derived growth factor binding transmembrane receptor protein phosphatase activity in PTC923-treated mice. Using CellChat, ligand-receptor interactions between injured ECs and mesangial cells are hypothesized via Pdgfd-Pdgfrb and Pdgfc-Pdgfra. In parallel, Col1a1 and Col3a1 as well as other genes associated with fibrosis were reduced with PTC923 in mesangial cells (Figure 3).

Conclusion: PTC923 therapy in the NZM2410 model of lupus nephritis reduces injured cells and genes associated with inflammation and fibrosis and increases EC expression of genes in pathways associated with ion channels and nitric oxide production. These data suggest that targeting eNOS uncoupling in ECs acts via reducing redox-regulated pathways and increasing nitric oxide production.

Supporting image 1UMAP of cell clusters identified by single nuclear RNA sequencing of from renal cortical cells from NZM2410 mice (n=5) treated with PTC923 (L-Sepiapterin, right side) or vehicle (left side) during active nephritis (28 weeks). Circled cell clusters indicate those that are different between groups. iEndo= injured endothelial cells, Endo=endothelial cells, iPT=injured proximal tubule cells, PTS1,2,3=proximal tubule segments 1,2, or 3), rPT=recovering proximal tubule cells, Podo=podocytes, MC=mesangial cells, MD=macula densa, etc.

Supporting image 2Graph indicating the percentage of cells in each cluster that are present in PTC923 (L-Sep, n=5) treated mice (salmon color) versus vehicle-treated mice (n=5, blue color). See figure 1. Additional cell types: DCT= distal convoluted tubule, CNT=connecting tubule, CPC=cortical principle cell, ICA=intercalated cell type A, ICB=intercalated cell type B, ATL=ascending thick limb or Henle, DTL=descending thick limb of Henle, Epi=parietyal epithelial cells, Uro=urothelial cells.

Supporting image 3Heatmap of differential gene expression from renal cortical cells of NZM2410 mice treated with L-Sepiapterin (PTC923) or vehicle from 22 to 28 weeks of age. Red indicates genes relatively increased in vehicle-treated mice, and blue indicates genes increased in PTC923-treated mice. Pdgf=platelet-derived growth factor, Col=collagen, Tnc=tenascin c, Fn1=fibronectin-1. iEndo= injured endothelial cells, Endo=endothelial cells, iPT=injured proximal tubule cells, PTS1,2,3=proximal tubule segments 1,2, or 3), rPT=recovering proximal tubule cells, Podo=podocytes, MC=mesangial cells, MD=macula densa, etc.


Disclosures: D. Russell: None; S. Moradi: None; S. Subramanian: None; S. Vaena: None; S. Mungaray: None; S. Hoffman: None; S. Berto: None; J. Oates: PTC Therapeutics, 12, PTC923 for this study provided by PTC Therapeutics.

To cite this abstract in AMA style:

Russell D, Moradi S, Subramanian S, Vaena S, Mungaray S, Hoffman S, Berto S, Oates J. L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/l-sepiapterin-treatment-reduces-renal-cortical-gene-expression-associated-with-oxidative-stress-and-fibrosis-in-nzm2410-murine-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/l-sepiapterin-treatment-reduces-renal-cortical-gene-expression-associated-with-oxidative-stress-and-fibrosis-in-nzm2410-murine-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology